JOHN SULLIVAN, MD
Osteopathic Medicine at Amgen Center Dr, Thousand Oaks, CA
License number
California 50369
Category
Osteopathic Medicine
Type
Internal Medicine
License number
California 50369
Category
Osteopathic Medicine
Type
Addiction Medicine
License number
California 50369
Category
Osteopathic Medicine
Type
Clinical Pharmacology
Address
Address
1 Amgen Center Dr, Thousand Oaks, CA 91320
Phone
(805) 447-4429
Professional information
Methods Of Using Osk1 Peptide Analogs
US Patent:
7825093, Nov 2, 2010
Filed:
Oct 25, 2007
Appl. No.:
11/978119
Inventors:
John K. Sullivan - Newbury Park CA, US
Joseph G. McGivern - Oak Park CA, US
Leslie P. Miranda - Thousand Oaks CA, US
Joseph G. McGivern - Oak Park CA, US
Leslie P. Miranda - Thousand Oaks CA, US
Assignee:
Amgen Inc. - Thousand Oaks CA
International Classification:
A61K 38/16, A61K 35/56, C07K 14/00
US Classification:
514 12, 424538, 530324
Abstract:
Disclosed is a composition of matter comprising an OSK1 peptide analog, and in some embodiments, a pharmaceutically acceptable salt thereof. A pharmaceutical composition comprises the composition and a pharmaceutically acceptable carrier. Also disclosed are DNAs encoding the inventive composition of matter, an expression vector comprising the DNA, and host cells comprising the expression vector. Methods of treating an autoimmune disorder and of preventing or mitigating a relapse of a symptom of multiple sclerosis are also disclosed.
Human Anti-Opgl Neutralizing Antibodies As Selective Opgl Pathway Inhibitors
US Patent:
7718776, May 18, 2010
Filed:
Apr 7, 2003
Appl. No.:
10/408901
Inventors:
William J. Boyle - Malibu CA, US
Eugene Medlock - Westlake CA, US
John J. Sullivan - Newbury Park CA, US
Robin L. Elliott - Newbury Park CA, US
Frank Martin - Newbury Park CA, US
Haichun Huang - Fremont CA, US
Eugene Medlock - Westlake CA, US
John J. Sullivan - Newbury Park CA, US
Robin L. Elliott - Newbury Park CA, US
Frank Martin - Newbury Park CA, US
Haichun Huang - Fremont CA, US
Assignee:
Amgen Inc. - Thousand Oaks CA
Medarex, Inc. - Princeton NJ
Medarex, Inc. - Princeton NJ
International Classification:
C12P 21/08, C07K 16/00, C12P 21/04, A61K 39/395
US Classification:
53038815, 4241331, 4241421, 4241451, 435 696, 435 7021, 5303873, 5303879, 53038823
Abstract:
Monoclonal antibodies and hybridomas producing them that interact with osteoprotegerin ligand (OPGL) are provided. Methods of treating osteopenic disorders by administering a pharmaceutically effective amount of antibodies to OPGL are also provided. Methods of detecting the amount of OPGL in a sample using antibodies to OPGL are further provided.
Human Anti-Opgl Neutralizing Antibodies As Selective Opgl Pathway Inhibitors
US Patent:
8367063, Feb 5, 2013
Filed:
May 18, 2010
Appl. No.:
12/782376
Inventors:
William J. Boyle - Malibu CA, US
Eugene Medlock - Westlake CA, US
John K. Sullivan - Newbury Park CA, US
Robin L. Elliott - Newbury Park CA, US
Frank Martin - Newbury Park CA, US
Haichun Huang - Fremont CA, US
Eugene Medlock - Westlake CA, US
John K. Sullivan - Newbury Park CA, US
Robin L. Elliott - Newbury Park CA, US
Frank Martin - Newbury Park CA, US
Haichun Huang - Fremont CA, US
Assignee:
Amgen, Inc. - Thousand Oaks CA
Medarex, Inc. - Princeton NJ
Medarex, Inc. - Princeton NJ
International Classification:
A61K 39/395, A61K 39/00, C07K 16/24, C07K 16/00
US Classification:
4241421, 4241451, 4241301, 53038815, 53038823, 5303871
Abstract:
Monoclonal antibodies and hybridomas producing them that interact with osteoprotegerin ligand (OPGL) are provided. Methods of treating osteopenic disorders by administering a pharmaceutically effective amount of antibodies to OPGL are also provided. Methods of detecting the amount of OPGL in a sample using antibodies to OPGL are further provided.
Selective Binding Agents Of Osteoprotegerin Binding Protein
US Patent:
2003010, Jun 5, 2003
Filed:
Feb 22, 2001
Appl. No.:
09/791153
Inventors:
Rajendra Deshpande - Thousand Oaks CA, US
Anna Hitz - Newbury Park CA, US
William Boyle - Malibu CA, US
John Sullivan - Newbury Park CA, US
Anna Hitz - Newbury Park CA, US
William Boyle - Malibu CA, US
John Sullivan - Newbury Park CA, US
Assignee:
Amgen Inc.
International Classification:
A61K039/395, C07K016/44
US Classification:
424/152100, 530/388100
Abstract:
Selective binding agents of osteoprotegerin binding protein (OPGbp) are provided by the invention. More particularly, the invention provides for antibodies and antigen binding domains which selectively bind to OPGbp and may be used to prevent or treat conditions relating to loss of bone mass. Nucleic acid molecules encoding said antibodies and antigen binding domains, and expression vectors and host cells for the production of same are also provided.
Human Anti-Opgl Neutralizing Antibodies As Selective Opgl Pathway Inhibitors
US Patent:
2013017, Jul 4, 2013
Filed:
Mar 11, 2013
Appl. No.:
13/794690
Inventors:
Amgen Inc. - Thousand Oaks CA, US
John K. Sullivan - Newbury Park CA, US
Robin L. Elliott - Newbury Park CA, US
Frank Martin - Newbury Park CA, US
Haichun Huang - Fremont Park CA, US
John K. Sullivan - Newbury Park CA, US
Robin L. Elliott - Newbury Park CA, US
Frank Martin - Newbury Park CA, US
Haichun Huang - Fremont Park CA, US
Assignee:
MEDAREX, INC. - Princeton NJ
AMGEN INC. - Thousand Oaks CA
AMGEN INC. - Thousand Oaks CA
International Classification:
C07K 16/24
US Classification:
4241581, 5303892, 5303873, 436501, 435 71
Abstract:
Monoclonal antibodies and hybridomas producing them that interact with osteoprotegerin ligand (OPGL) are provided. Methods of treating osteopenic disorders by administering a pharmaceutically effective amount of antibodies to OPGL are also provided. Methods of detecting the amount of OPGL in a sample using antibodies to OPGL are further provided.
Methods Of Using Conjugated Toxin Peptide Therapeutic Agents
US Patent:
7910102, Mar 22, 2011
Filed:
Oct 25, 2007
Appl. No.:
11/978111
Inventors:
John K. Sullivan - Newbury Park CA, US
Joseph G. McGivern - Oak Park CA, US
Leslie P. Miranda - Thousand Oaks CA, US
Hung Q. Nguyen - Thousand Oaks CA, US
Kenneth W. Walker - Newbury Park CA, US
Taruna Arora Khare - Thousand Oaks CA, US
Beverly S. Adler - Newbury Park CA, US
Francis H. Martin - Newbury Park CA, US
Joseph G. McGivern - Oak Park CA, US
Leslie P. Miranda - Thousand Oaks CA, US
Hung Q. Nguyen - Thousand Oaks CA, US
Kenneth W. Walker - Newbury Park CA, US
Taruna Arora Khare - Thousand Oaks CA, US
Beverly S. Adler - Newbury Park CA, US
Francis H. Martin - Newbury Park CA, US
Assignee:
Amgen Inc. - Thousand Oaks CA
International Classification:
A61K 39/00, A61K 38/16
US Classification:
4241341, 514 213
Abstract:
Disclosed is a composition of matter comprising an OSK1 peptide analog, and in some embodiments, a pharmaceutically acceptable salt thereof. A pharmaceutical composition comprises the composition and a pharmaceutically acceptable carrier. Also disclosed are DNAs encoding the inventive composition of matter, an expression vector comprising the DNA, and host cells comprising the expression vector. Methods of treating an autoimmune disorder and of preventing or mitigating a relapse of a symptom of multiple sclerosis are also disclosed.
Human Anti-Opgl Neutralizing Antibodies As Selective Opgl Pathway Inhibitors
US Patent:
2010020, Aug 19, 2010
Filed:
Feb 15, 2010
Appl. No.:
12/705962
Inventors:
William J. Boyle - Malibu CA, US
Eugene Medlock - Westlake CA, US
John K. Sullivan - Newbury Park CA, US
Robin L. Elliott - Newbury Park CA, US
Frank Martin - Newbury Park CA, US
Haichun Huang - Fremont CA, US
Eugene Medlock - Westlake CA, US
John K. Sullivan - Newbury Park CA, US
Robin L. Elliott - Newbury Park CA, US
Frank Martin - Newbury Park CA, US
Haichun Huang - Fremont CA, US
Assignee:
AMGEN INC. - Thousand Oaks CA
MEDAREX, INC. - Princeton NJ
MEDAREX, INC. - Princeton NJ
International Classification:
A61K 39/395, C07K 16/24, C07H 21/04, C12N 15/63, C12N 5/10, C12P 21/02, A61P 19/10, A61P 19/08
US Classification:
4241581, 5303892, 536 2353, 4353201, 435358, 435 696
Abstract:
Monoclonal antibodies and hybridomas producing them that interact with osteoprotegerin ligand (OPGL) are provided. Methods of treating osteopenic disorders by administering a pharmaceutically effective amount of antibodies to OPGL are also provided. Methods of detecting the amount of OPGL in a sample using antibodies to OPGL are further provided.
B7-Like Molecules And Uses Thereof
US Patent:
2002016, Nov 7, 2002
Filed:
Jun 29, 2001
Appl. No.:
09/896738
Inventors:
Gary Fox - Newbury Park CA, US
John Sullivan - Newbury Park CA, US
Mei Fang - Thousand Oaks CA, US
John Sullivan - Newbury Park CA, US
Mei Fang - Thousand Oaks CA, US
Assignee:
Amgen, Inc.
International Classification:
C12P021/02, C07H021/04, C07K014/435, C12N005/06
US Classification:
530/350000, 536/023200, 435/325000, 435/069100, 435/320100
Abstract:
The present invention provides B7-Like (B7-L) polypeptides and nucleic acid molecules encoding the same. The invention also provides selective binding agents, vectors, host cells, and methods for producing B7-L polypeptides. The invention further provides pharmaceutical compositions and methods for the diagnosis, treatment, amelioration, and/or prevention of diseases, disorders, and conditions associated with B7-L polypeptides.
Osk1 Peptide Analogs And Pharmaceutical Compositions
US Patent:
7803769, Sep 28, 2010
Filed:
Oct 25, 2007
Appl. No.:
11/978110
Inventors:
John K. Sullivan - Newbury Park CA, US
Joseph G. McGivern - Oak Park CA, US
Leslie P. Miranda - Thousand Oaks CA, US
Joseph G. McGivern - Oak Park CA, US
Leslie P. Miranda - Thousand Oaks CA, US
Assignee:
Amgen Inc. - Thousand Oaks CA
International Classification:
A61K 38/16, A61K 35/56, C07K 14/00
US Classification:
514 12, 530324, 424538
Abstract:
Disclosed is a composition of matter comprising an OSK1 peptide analog, and in some embodiments, a pharmaceutically acceptable salt thereof. A pharmaceutical composition comprises the composition and a pharmaceutically acceptable carrier. Also disclosed are DNAs encoding the inventive composition of matter, an expression vector comprising the DNA, and host cells comprising the expression vector. Methods of treating an autoimmune disorder and of preventing or mitigating a relapse of a symptom of multiple sclerosis are also disclosed.
Conjugated Toxin Peptide Therapeutic Agents
US Patent:
7820623, Oct 26, 2010
Filed:
Oct 25, 2007
Appl. No.:
11/978076
Inventors:
John K. Sullivan - Newbury Park CA, US
Joseph G. McGivern - Oak Park CA, US
Leslie P. Miranda - Thousand Oaks CA, US
Hung Q. Nguyen - Thousand Oaks CA, US
Kenneth W. Walker - Newbury Park CA, US
Taruna Arora Khare - Thousand Oaks CA, US
Beverly S. Adler - Newbury Park CA, US
Francis H. Martin - Newbury Park CA, US
Joseph G. McGivern - Oak Park CA, US
Leslie P. Miranda - Thousand Oaks CA, US
Hung Q. Nguyen - Thousand Oaks CA, US
Kenneth W. Walker - Newbury Park CA, US
Taruna Arora Khare - Thousand Oaks CA, US
Beverly S. Adler - Newbury Park CA, US
Francis H. Martin - Newbury Park CA, US
Assignee:
Amgen Inc. - Thousand Oaks CA
International Classification:
A61K 38/00
US Classification:
514 12, 514 13
Abstract:
Disclosed is a composition of matter comprising an OSK1 peptide analog, and in some embodiments, a pharmaceutically acceptable salt thereof. A pharmaceutical composition comprises the composition and a pharmaceutically acceptable carrier. Also disclosed are DNAs encoding the inventive composition of matter, an expression vector comprising the DNA, and host cells comprising the expression vector. Methods of treating an autoimmune disorder and of preventing or mitigating a relapse of a symptom of multiple sclerosis are also disclosed.